Ru Catalyzed Divergence
A R T I C L E S
2. General Procedures for the Synthesis of Valerolactones. 2.a.
Preparation of Valerolactone 6 from Alcohol 5. By using method A
in Table 2, a mixture of alcohol 5 (135 mg, 0.742 mmol), catalyst 9c
(67 mg, 0.074 mmol), ligand 2c (104 mg, 0.296 mmol), N-hydroxy-
succinimide (511 mg, 4.44 mmol), sodium bicarbonate (124 mg, 1.48
mmol), tetra-n-butylammonium hexafluorophosphate (86 mg, 0.222
mmol) in DMF (1.9 mL, 0.4M) was placed in a preheated oil bath at
85 °C and stirred at that temperature under N2 for 23 h. The reaction
mixture was cooled to room temperature and diluted with ether (30
mL) and washed with water (2 × 10 mL). The aqueous layer was
extracted with ether (2 × 25 mL). The organic layers were combined,
dried over MgSO4, and concentrated. The residual oil was purified by
column chromatography (with deactivated silica gel, eluted with pet-
ether/EtOAc 20:1) to provide dihydropyran 7 (10 mg, 0.052 mmol,
7%). Further elution (with pet-ether/EtOAc 4:1) provided a trace amount
of starting material (<1 mg) and valerolactone 6 (101 mg, 0.509 mmol)
as clear oil (69% yield). The spectral data are in full accord with the
reported value.11 Rf 0.50 (pet-ether/EtOAc 7:1).
IV. Summary
In this article, we described a divergent ruthenium-catalyzed
reaction from bis-homopropargylic alcohols that provides a
convenient access to either dihydropyrans or valerolactones.
Unlike homopropargylic alcohols, the reactions of bis-homopro-
pargylic alcohols required the use of excess phosphines to avoid
the undesired exo-cyclization pathway. Furthermore, either
cycloisomerization to dihydropyrans or oxidative cyclization to
δ-valerolactones may be performed. The divergence described
here is remarkable because it derives only by choice and amount
of phosphine ligands, a flexibility not previously observed.
V. Experimental
1. General Procedures for the Synthesis of Dihydropyrans. 1.a.
Preparation of Dihydropyran 7 from Alcohol 5. By using method
C in Table 2, a mixture of alcohol 5 (140 mg, 0.768 mmol), catalyst
9e (32 mg, 0.038 mmol), ligand 2e (49 mg, 0.15 mmol), 4 sodium salt
(53 mg, 0.38 mmol), and tetra-n-butylammonium hexafluorophosphate
(39 mg, 0.10 mmol) in DMF (1.9 mL, 0.4 M) was placed in a preheated
oil bath at 85 °C and stirred at that temperature under N2 for 25 h. The
reaction mixture was cooled to room temperature and diluted with ether
(30 mL) and washed with water (2 × 10 mL). The aqueous layer was
extracted with ether (2 × 25 mL). The organic layers were combined,
dried over MgSO4, and concentrated. The residual oil was purified by
column chromatography (with deactivated silica gel, eluted with pet-
ether/EtOAc 20:1) to provide dihydropyran 7 (91 mg, 0.50 mmol) as
clear oil (64% yield) Rf 0.70 (pet-ether/EtOAc 20:1).
IR (neat film): ν 2928, 2857, 1736, 1465, 1378, 1342, 1241, 1178,
1
1046 cm-1. H NMR (CDCl3, 300 MHz): δ 4.26(m, 1H), 2.41-2.62
(m, 2H), 1.20-2.00(m, 16H), 0.87(t, J ) 6.4 Hz, 3H). 13C NMR
(CDCl3, 75 MHz): δ 172.0, 80.6, 35.8, 31.7, 29.5, 29.3, 29.1, 27.8,
24.9, 22.6, 18.5, 14.1.
2.b. Preparation of Valerolactone 17 from Alcohol 16. By using
the same procedure, a mixture of 16 (260 mg, 0.551 mmol), catalyst
9c (50 mg, 0.0551 mmol), ligand 2c (78 mg, 0.22mol), N-hydroxysuc-
cinimide (380 mg, 3.31 mmol), sodium bicarbonate (93 mg, 1.1 mmol),
tetra-n-butylammonium hexafluorophosphate (64 mg, 0.17 mmol) in
DMF (1.4 mL, 0.4M) was placed in a preheated oil bath at 85 °C and
stirred at that temperature for 26 h. The reaction mixture was cooled
to room temperature, and DMF was removed under reduced pressure.
The reaction mixture was purified directly by column chromatograhy
(with deactivated silica gel, eluted with pet-ether/EtOAc 20:1) to give
the dihydropyran (18 mg, 0.038, 7% yield). Further elution (with pet-
ether/EtOAc 4:1) provided the starting material (2 mg, ∼1%) and the
valerolactone 17 (175 mg, 0.358 mmol) as a clear oil (65% yield).
[R]D 70.7 (c 1.11, CHCl3). Rf 0.55 (pet-ether/EtOAc 4:1).
IR (neat film): ν 2928, 2856, 1730, 1461, 1260, 1121, 1033 cm-1
.
1H NMR (CDCl3, 300 MHz): δ 6.36(d, J ) 5.7 Hz, 1H), 4.65(m, 1H),
3.84(m, 1H), 1.85-2.10(m, 2H), 1.15-1.80(m, 14H), 0.88(t, J ) 6.5
Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 143.8, 100.3, 75.2, 35.3, 31.8,
29.6, 29.3, 27.8, 25.3, 22.7, 19.9, 14.1. HRMS: Calcd for C12H22O
(M+): 182.1671. Found: 182.1673.
Further elution (with pet-ether/EtOAc 4:1) provided unreacted
starting material 5 (∼1 mg) and the lactone 6 as clear oil (6 mg, 0.03
mmol, 4% yield).
1.b. Preparation of Dihydropyran 18 from Alcohol 16. With the
same method, a mixture of 16 (238 mg, 0.503 mmol), ruthenium catalyst
9e (21 mg, 0.025 mmol), phosphine ligand 2e (32 mg, 0.10 mmol), 4
sodium salt (35 mg, 0.25 mmol), and tetra-n-butylammonium hexafluo-
rophosphate (29 mg, 0.076 mmol) in DMF (1.3 mL, 0.4M) was placed
in a preheated oil bath at 85 °C and stirred at that temperature for 26
h. The reaction mixture was cooled to room temperature. DMF was
removed under reduced pressure, and the reaction mixture was purified
directly with column chromatography (with deactivated silica gel, eluted
with pet-ether/EtOAc 20:1) to give the title compound 6b as clear oil
(162 mg, 0.344 mmol, 68% yield). The spectral data are in full accord
with the reported value.20 [R]D 50.5 (c 2.10, CHCl3). Rf 0.75 (pet-ether/
EtOAc 10:1).
IR (neat film): ν 3030, 2867, 1950, 1749, 1595, 1497, 1454, 1366,
1
1310, 1252, 1203 cm-1. H NMR (CDCl3, 300 MHz): δ 7.03-7.40
(m, 15H), 5.03(d, J ) 11.0 Hz, 1H), 4.85(d, J ) 10.5 Hz, 1H), 4.78(d,
J ) 11.0 Hz, 1H), 4.60(d, J ) 12.1 Hz, 1H), 4.56(d, J ) 12.1 Hz,
1H), 4.48(d, J ) 10.5 Hz, 1H), 4.11(m, 1H), 3.60-3.82(m, 6H), 2.80-
(ddd, J ) 17.6, 9.5, 5.9 Hz, 1H), 2.61(m, 1H), 2.20(m, 1H), 1.96(m,
1H). 13C NMR (CDCl3, 75 MHz): δ 170.3, 138.1, 137.8, 137.7, 128.4,
128.1, 127.9, 127.8, 127.7, 94.0, 83.7, 81.3, 79.2, 77.2, 75.4, 73.5, 72.1,
68.6, 27.6, 24.3. HRMS: Calcd for C30H32O6 (M+): 488.2199.
Found: 488.2193.
IR (neat film): ν 3064, 3030, 2859, 1649, 1497, 1454, 1362, 1320,
1238, 1209, 1107, 1068 cm-1. H NMR (CDCl3, 300 MHz): 7.11-
1
Acknowledgment. We thank the National Institutes of Health
and the National Science Foundation for their generous support
of our program. Mass spectra were provided by the Mass
Spectrometry Facility at the University of California-San
Francisco supported by NIH Division of Research Resources.
7.41(m, 15H), 6.39(d, J ) 5.6 Hz, 1H), 4.99(d, J ) 11.0 Hz, 1H),
4.90(d, J ) 10.7 Hz, 1H), 4.86(d, J ) 10.7 Hz, 1H), 4.79(d, J ) 11.0
Hz, 1H), 4.71(m, 1H), 4.62(d, J ) 12.2 Hz, 1H), 4.54(d, J ) 12.2 Hz,
1H), 3.40-3.60(m, 7H), 2.40(m, 1H), 2.20(m, 1H). 13C NMR (CDCl3,
75 MHz): δ 142.8, 138.7, 138.1, 137.9, 128.4, 128.3, 127.9, 127.8,
127.7, 127.6, 127.5, 98.3, 84.2, 79.1, 78.8, 77.4, 75.2, 74.9, 73.5, 72.2,
68.9, 26.7.
Supporting Information Available: Detailed descriptions of
experimental procedures and spectral data for all new com-
pounds (PDF). This material is available free of charge via the
Further elution (with pet-ether/EtOAc :1) provided starting material
(2 mg, 0.005 mmol, 1%) and lactone 17 (17 mg, 0.026 mmol, 5%).
(33) The poor reactivity of tertiary bis-homopropargylic alcohols with stoichio-
metric amount of molybdenum complexes has been addressed: Weyer-
shausen, B.; Nieger, M.; Dotz, K. H. J. Organomet. Chem. 2000, 602, 37.
JA011840W
9
J. AM. CHEM. SOC. VOL. 124, NO. 11, 2002 2533